Common cancer-associated PIK3CA activating mutations rarely occur in Langerhans cell histiocytosis

Blood

Volumn 125, Issue 15, 2015, Pages 2448-2449

  Héritier, Sébastien ^a,b   Saffroy, Raphael ^c   Radosevic Robin, Nina ^d,e   Pothin, Yolaine ^f   Pacquement, Héléne ^g   Peuchmaur, Michel ^h   Lemoine, Antoinette ^c   Haroche, Julien ⁱ   Donadieu, Jean ^a,b   Emile, Jean Francois ^b,f  

^a ARMAND TROUSSEAU HOSPITAL   (France)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^c HÔPITAL PAUL BROUSSE   (France)

^d CENTRE JEAN PERRIN   (France)

^e UNIVERSITÉ CLERMONT AUVERGNE   (France)

^f HÔPITAL AMBROISE PARÉ   (France)

^g INSTITUT CURIE   (France)

^h HÔPITAL ROBERT DEBRÉ   (France)

ⁱ PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; GENOMIC DNA; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PIK3CA PROTEIN, HUMAN;

ADULT; AGED; CHILD; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME PHOSPHORYLATION; ERDHEIM CHESTER DISEASE; FEMALE; FOLLOW UP; GENE; GENE IDENTIFICATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENOTYPE; HISTIOCYTE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LANGERHANS CELL; LANGERHANS CELL HISTIOCYTOSIS; LETTER; MAJOR CLINICAL STUDY; MISSENSE MUTATION; PATHOGENESIS; PIK3CA GENE; PRIORITY JOURNAL; SCHOOL CHILD; SIGNAL TRANSDUCTION; SOMATIC MUTATION; SWELLING; VERY ELDERLY; ADOLESCENT; GENETICS; INFANT; MALE; MIDDLE AGED; MUTATION; NEOPLASM; PATHOLOGY; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; INFANT; MALE; MIDDLE AGED; MUTATION; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; YOUNG ADULT;

EID: 84927673688     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-01-625491     Document Type: Letter

References (10)

1. Badalian-Very G, Vergilio J-A, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116(11):1919-1923.
2. Nelson DS, Quispel W, Badalian-Very G, et al. Somatic activating ARAF mutations in Langerhans cell histiocytosis. Blood. 2014;123(20):3152-3155.
3. Brown NA, Furtado LV, Betz BL, et al. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. Blood. 2014;124(10):1655-1658.
4. Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci. 2011;36(6):320-328.
5. Emile J-F, Diamond EL, Hélias-Rodzewicz Z, et al. Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. Blood. 2014;124(19):3016-3019.
6. Badalian-Very G. A common progenitor cell in LCH and ECD. Blood. 2014;124(7):991-992.
7. Janku F, Lee JJ, Tsimberidou AM, et al. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS ONE. 2011;6(7):e22769.
8. Miled N, Yan Y, Hon W-C, et al. Mechanism of two classes of cancer mutations in the phosphoinositide 3-kinase catalytic subunit. Science. 2007;317(5835):239-242.
9. Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304(5670):554.
10. Arceci R, Allen CE, Dunkel I, et al. Evaluation of afuresertib, an oral pan-AKT inhibitor, in patients with Langerhans cell histiocytosis [abstract]. Blood. 2013;122(21):2907. Abstract 802.